Add-on treatment with Diacomit (stiripentol) was associated with reductions in the number of episodes of status epilepticus (SE), periods of prolonged seizure activity, in people with Dravet syndrome and other types of epilepsy, a review study found. Evidence also suggested that Diacomit may be able to stop…
Two-thirds of 24 children and young adults with Dravet syndrome experienced clinically meaningful declines in seizure frequency after adding Fintepla (fenfluramine) to their treatment regimen, according to a real-world Danish analysis. Fintepla’s use also was associated with reductions in healthcare utilization and the use of other anti-seizure medications.
Add-on therapies Diacomit (stiripentol) and Fintepla (fenfluramine) were found to be more effective for seizure control in Dravet syndrome patients than Epidiolex (cannabidiol) in a recent indirect analysis of clinical trial data. Overall, Diacomit was best for stopping seizures altogether, and was associated with fewer treatment…
The severity of seizures was reduced among Dravet syndrome patients in the U.K. over 10 years, but developmental outcomes worsened, a recent analysis shows. Children younger than age 6 generally tended to see a worse trajectory during that period than older patients, including having a higher burden of coexisting…
Treatment with the investigational therapy STK-001 led to significant reductions in seizure frequency and clinically meaningful improvements in cognition and behavior for children and adolescents with Dravet syndrome, according to data from Phase 1/2 studies and their open-label extensions (OLEs). Developer Stoke Therapeutics said that the findings…
Fycompa (perampanel) was found to safely reduce seizure frequency among patients with genetic forms of epilepsy, including Dravet syndrome, in a recent analysis of real-world treatment data. Findings from the analysis of pooled clinical practice data showed treatment responses among these genetic epilepsy patients were at least as…
A molecule designed to enhance activity at certain GABA-A receptor proteins in the brain protected against seizures and eased anxiety in a mouse model of Dravet syndrome, recent research showed. At higher doses, the medication led to sedative side effects, which scientists believe can be avoided by making sure…
Behavioral development in children and teens with Dravet syndrome generally held stable in the first year of an observational study, though some showed small improvements in communication, according to researchers. Participants in the study, dubbed BUTTERFLY, continued to perform below what would be expected of their typically developing peers…
Real-world use of Fintepla (fenfluramine) was found to be safe and effective for people with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), according to a recent report from Spain. Data, which showed that 60.3% of Dravet patients experienced a clinically meaningful reduction in seizures, are generally consistent with…
Most Dravet syndrome patients utilize various types of therapies beyond medicines to manage the disease, including physiotherapy, occupational therapy, and psychological therapy, according to a recent survey of caregivers and family members in Spain. While survey respondents sometimes found these non-pharmacological interventions to be effective, sizable numbers were less…
Get regular updates to your inbox.